{
    "2021-02-03": [
        [
            {
                "time": "",
                "original_text": "JPMorgan Chase & Co.减持康龙化成股份约184.89万股 减持股份",
                "features": {
                    "keywords": [
                        "JPMorgan",
                        "减持",
                        "康龙化成",
                        "股份"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "HSBC Global Asset Management (Hong Kong) Limited减持康龙化成股份约22.38万股 减持股份",
                "features": {
                    "keywords": [
                        "HSBC",
                        "减持",
                        "康龙化成",
                        "股份"
                    ],
                    "sentiment_score": -0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【异动股】康龙化成(03759-HK)涨3.03%",
                "features": {
                    "keywords": [
                        "康龙化成",
                        "涨",
                        "异动股"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "68只港股获南向资金大比例持有",
                "features": {
                    "keywords": [
                        "港股",
                        "南向资金",
                        "大比例持有"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "医药生物2月月报：寻业绩主线 重点关CXO等高增长赛道",
                "features": {
                    "keywords": [
                        "医药生物",
                        "业绩",
                        "CXO",
                        "高增长赛道"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}